Medtronic

Medtronic PLC: Addenda Capital Sells 7,977 Shares, Holdings Valued at $7.06M

CCLA Investment Management Increases Stake in Medtronic PLC with $13 Million Purchase

美敦力

Medtronic announces CE Mark and first US trial for Affera Sphere-360 catheter.

Anteris Technologies

Anteris Secures $320m Funding, Medtronic Invests $90m in Structural Heart Company

Anteris Announces $320 Million Capital Raise with Medtronic Strategic Investment

Catalyst<ul> <li>All three active analysts rate MDT as Buy, showing strong institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value and shows favorable asset-to-market-value ratios.</li> <li>Large fund flows show a positive overall trend, indicating institutional buying pressure.</li></ul>Risk<ul> <li>Technical indicators show a volatile market environment with bearish signals dominating in recent periods.</li> <li>Fund flows for small and medium orders are negative, suggesting retail or smaller institutional outflows.</li></ul>

Key Factors

Medtronic announced CE Mark and first U.S. IDE trial cases for its Affera Sphere-360 catheter, a first-of-its-kind mapping and single-shot PFA device for paroxysm AF treatment.Medtronic invested $90 million in Anteris Technologies as part of a $320 million capital raise to support the PARADIGM trial for the DurAVR Transcatheter Heart Valve and advance TAVR technology.Addenda Capital Inc. reduced its Medtronic stake by 9.85%, selling 7,977 shares valued at $7.06 million, according to a 13F filing.CCLA Investment Management increased its stake in Medtronic by 4.22%, purchasing 5,490 shares valued at $13.03 million.

Recent Updates

MDT News